دورية أكاديمية

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

التفاصيل البيبلوغرافية
العنوان: Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
المؤلفون: Bardia, A., Messersmith, W.A., Kio, E.A., Berlin, J.D., Vahdat, L., Masters, G.A., Moroose, R., Santin, A.D., Kalinsky, K., Picozzi, V., O'Shaughnessy, J., Gray, J.E., Komiya, T., Lang, J.M., Chang, J.C., Starodub, A., Goldenberg, D.M., Sharkey, R.M., Maliakal, P., Hong, Q., Wegener, W.A., Goswami, T., Ocean, A.J.
المصدر: In Annals of Oncology June 2021 32(6):746-756
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2021.03.005